Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?

Mondello P, Steiner N, Willenbacher W, Ferrero S, Ghione P, Marabese A, Pitini V, Cuzzocrea S, Mian M.

Oncologist. 2016 Sep;21(9):1107-12. doi: 10.1634/theoncologist.2016-0103. Epub 2016 Jul 5.

2.

Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?

Mondello P, Mian M, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, Mandolfino M, Santoro D, Mondello S, Aloisi C, Altavilla G, Benvenga S.

Curr Oncol. 2016 Jun;23(3):e165-70. doi: 10.3747/co.23.3026. Epub 2016 Jun 9.

3.

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M.

Ann Hematol. 2016 Jun;95(7):1107-14. doi: 10.1007/s00277-016-2668-0. Epub 2016 Apr 22.

PMID:
27103007
4.

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.

Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M.

Exp Hematol Oncol. 2016 Jan 6;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015.

5.

90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?

Mondello P, Steiner N, Willenbacher W, Arrigo C, Cuzzocrea S, Pitini V, Mian M.

Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):82-8. doi: 10.1016/j.clml.2015.11.014. Epub 2015 Nov 21.

PMID:
26702476
6.

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, Del Poeta G, Mauro FR, Cortelezzi A, Borza PA, Ghio F, Mondello P, Murru R, Gozzetti A, Cariccio MR, Piccirillo N, Boncompagni R, Cantonetti M, Principe MI, Reda G, Bongarzoni V, Cervetti G, Pitini V, Foà R, Sica S, D'Arena G.

Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.

PMID:
26307523
7.

Thyroid function, autoimmunity and nodules in hematological malignancies.

Mondello P, Sindoni A, Pitini V, Scisca C, Altavilla G, Benvenga S.

Arch Endocrinol Metab. 2015 Jun;59(3):236-44. doi: 10.1590/2359-3997000000044.

8.

Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.

Santarpia M, Altavilla G, Pitini V, Rosell R.

Future Oncol. 2015;11(8):1259-74. doi: 10.2217/fon.14.320. Review.

PMID:
25832881
9.

Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?

Mondello P, Cuzzocrea S, Pitini V, Aloisi C, Mian M.

Acta Oncol. 2015 Jun;54(6):953-5. doi: 10.3109/0284186X.2015.1027410. Epub 2015 Apr 1. No abstract available.

PMID:
25831143
10.

Should the use of surveillance imaging in diffuse large B-cell lymphoma be discontinued?

Pitini V, Arrigo C, Di Mirto C, Garufi L, Mondello P, d'Aquino A, Altavilla G.

J Clin Oncol. 2015 May 10;33(14):1623. doi: 10.1200/JCO.2014.60.0627. Epub 2015 Mar 23. No abstract available.

PMID:
25800759
11.

Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.

Mondello P, Mian M, Aloisi C, Famà F, Mondello S, Pitini V.

Nutr Cancer. 2015;67(1):12-26. doi: 10.1080/01635581.2015.976318. Epub 2014 Dec 16. Review.

PMID:
25513730
12.

Emerging markers of cachexia predict survival in cancer patients.

Mondello P, Lacquaniti A, Mondello S, Bolignano D, Pitini V, Aloisi C, Buemi M.

BMC Cancer. 2014 Nov 16;14:828. doi: 10.1186/1471-2407-14-828.

13.

Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal?

Mondello P, Steiner N, Wasle I, Pitini V, Mian M.

Anticancer Res. 2014 Nov;34(11):6701-4.

PMID:
25368277
15.

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease.

Mondello P, Mian M, Arrigo C, Pitini V.

Springerplus. 2014 Jul 7;3:342. doi: 10.1186/2193-1801-3-342. eCollection 2014.

16.

Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature.

Mondello P, Pitini V, Arrigo C, Mondello S, Mian M, Altavilla G.

Springerplus. 2014 Mar 5;3:123. doi: 10.1186/2193-1801-3-123. eCollection 2014.

17.

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF.

Blood. 2014 Jun 5;123(23):3574-7. doi: 10.1182/blood-2014-02-555607. Epub 2014 Mar 31.

18.

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G.

Lung Cancer. 2013 Oct;82(1):171-2. doi: 10.1016/j.lungcan.2013.07.004. Epub 2013 Aug 9.

PMID:
23932362
19.

Questionable validity of cardiac risk score on the basis of the NSABP B-31 model.

Pitini V, Arrigo C, Mondello P, Altavilla G.

J Clin Oncol. 2013 Jun 10;31(17):2224. doi: 10.1200/JCO.2012.47.2696. Epub 2013 May 6. No abstract available.

PMID:
23650420
20.

Circulating mitotic figures in a patient with dual infection by Epstein-Barr virus and cytomegalovirus.

Pitini V, Arrigo C, Mondello P, Sturniolo G, Altavilla G.

Eur J Haematol. 2015 Jan;94(1):89. doi: 10.1111/ejh.12132. Epub 2013 Jun 28. No abstract available.

PMID:
23646993
21.

Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma.

Pitini V, Rizzo M, Arrigo C, Mondello P, Altavilla G.

Case Rep Hematol. 2012;2012:803298. doi: 10.1155/2012/803298. Epub 2012 Dec 26.

22.

Risk of second malignant neoplasm among patients with lymphoma.

Pitini V, Arrigo C, Sauta MG, Altavilla G.

J Clin Oncol. 2011 Oct 1;29(28):3834; author reply 3834-5. doi: 10.1200/JCO.2011.37.2144. Epub 2011 Aug 29. No abstract available.

PMID:
21876085
23.

Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.

Pitini V, Cascio A, Arrigo C, Altavilla G.

Br J Haematol. 2012 Jan;156(1):1. doi: 10.1111/j.1365-2141.2011.08802.x. Epub 2011 Jul 25. No abstract available.

PMID:
21790529
24.

Secondary Leukemia in a non-Hodgkin's Lymphoma Patient Presenting as Myeloid Sarcoma of the Breast.

Pitini V, Arrigo C, Sauta MG, Altavilla G.

Case Rep Hematol. 2011;2011:914613. doi: 10.1155/2011/914613. Epub 2011 Jul 12.

25.

Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.

Curtò L, Torre ML, Ferraù F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavò S.

ScientificWorldJournal. 2010 Nov 4;10:2132-8. doi: 10.1100/tsw.2010.210. Review.

26.

The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes.

Pitini VV.

Leuk Res. 2011 Jan;35(1):32-3. doi: 10.1016/j.leukres.2010.07.007. Epub 2010 Jul 31. No abstract available.

PMID:
20674019
27.

How cells respond to interferons.

Pitini V, Arrigo C, Altavilla G.

J Clin Oncol. 2010 Sep 1;28(25):e439; author reply e440. doi: 10.1200/JCO.2010.28.9603. Epub 2010 Jul 19. No abstract available.

PMID:
20644099
28.

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.

Pitini V, Sturniolo G, Arrigo C, Leonardi S, Pino S, Altavilla G.

Br J Haematol. 2010 Jul;150(1):116-8. doi: 10.1111/j.1365-2141.2010.08154.x. Epub 2010 Mar 8. No abstract available.

PMID:
20230413
29.

Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time.

Pozzi S, Marcheselli R, Falorio S, Masini L, Stelitano C, Falcone A, Quarta G, Ponchio L, Pitini V, Luminari S, Baldini L; Gruppo Italiano Studio Linfomi (GISL).

Am J Hematol. 2009 Dec;84(12):850-2. doi: 10.1002/ajh.21553. No abstract available.

30.

Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.

Pitini V, Arrigo C, Sauta MG, Altavilla G.

Leuk Res. 2009 Sep;33(9):e143-4. doi: 10.1016/j.leukres.2009.04.012. Epub 2009 May 13.

PMID:
19443031
31.

Dasatinib induces a response in chronic lymphocytic leukemia.

Pitini V, Arrigo C, Altavilla G.

Blood. 2009 Jan 8;113(2):498. doi: 10.1182/blood-2008-09-178822. No abstract available.

32.

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.

Pitini V, Arrigo C, Altavilla G.

J Clin Oncol. 2008 Jul 20;26(21):3645-6. doi: 10.1200/JCO.2008.17.0357. No abstract available.

PMID:
18640945
33.

Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.

Altavilla G, Arrigo C, Santarpia MC, Galletti G, Picone G, Marabello G, Tomasello C, Pitini VV.

J Neurooncol. 2008 Oct;90(1):31-3. doi: 10.1007/s11060-008-9623-4. Epub 2008 Jun 20.

PMID:
18566747
34.

Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma.

Pitini V, Arrigo C, Alafaci C, Altavilla G.

J Neurooncol. 2008 Jun;88(2):227-9. doi: 10.1007/s11060-008-9558-9.

PMID:
18317687
35.

Gene expression profiling does not identify molecular subgroup among nodal peripheral T-cell lymphomas.

Pitini V, Arrigo C, Altavilla G.

J Clin Oncol. 2007 Oct 20;25(30):4851; author reply 4851-2. No abstract available.

PMID:
17947737
36.

Interleukin-2 and lymphokine-activated killer cell therapy in patients with relapsed B-cell lymphoma treated with rituximab.

Pitini V, Arrigo C, Naro C, Altavilla G.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5497. No abstract available.

37.

Efficacy and safety of bortezomib in patients with plasma cell leukemia.

Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A; GISMM Cooperative Group; GISL Cooperative Group; GIMEMA Cooperative Group.

Cancer. 2007 Jun 1;109(11):2285-90.

38.

Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.

Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G; Gruppo Italiano Studio Linfomi.

Leuk Lymphoma. 2007 Jan;48(1):56-64.

PMID:
17325848
39.

Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.

Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F.

J Neurooncol. 2007 Jul;83(3):291-3. Epub 2007 Jan 24.

PMID:
17245621
40.

Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?

Pitini V, Arrigo C, Altavilla G, Naro C.

Leuk Res. 2007 Jul;31(7):1027-8. Epub 2006 Nov 28. No abstract available.

PMID:
17134751
41.

Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?

Pitini V, Arrigo C, Altavilla G, Naro C, Righi M.

Leuk Res. 2007 May;31(5):725-6. Epub 2006 Sep 15. No abstract available.

PMID:
16978696
42.

Pitfalls of positron emission tomography for assessing relapse in Hodgkin's disease: a case report.

Pitini V, Navarra G, Cavallari V, Arrigo C, Naro C, Altavilla G.

Haematologica. 2006 Aug;91(8 Suppl):ECR38.

43.

An accessory spleen wrongly recognised as relapse by positron emission tomography.

Pitini V, Navarra G, Cavallari V, Arrigo C.

Eur J Haematol. 2006 Sep;77(3):270-1. No abstract available.

PMID:
16923117
44.

An acute-leukaemia-like picture due to breast carcinoma cells.

Pitini V, Arrigo C, Altavilla G.

Lancet Oncol. 2006 Jun;7(6):524. No abstract available.

PMID:
16750505
45.

Surgical treatment for congestive heart failure with autologous adult stem cell transplantation.

Pitini V, Altavilla G, Arrigo C.

J Thorac Cardiovasc Surg. 2006 May;131(5):1213-4; author reply 1214. No abstract available.

46.

Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.

Pitini V, Sturniolo G, Cavallari V, Arrigo C.

Br J Haematol. 2006 Jan;132(2):123. No abstract available.

PMID:
16398645
47.

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.

Pitini V, Arrigo C, Righi M.

Cancer. 2005 Sep 15;104(6):1332-3; author reply 1333. No abstract available.

48.

Limitations of molecular detection of CK19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically negative axillary lymph nodes.

Pitini V, Arrigo C, Amata C, La Torre I.

Ann Oncol. 2005 Nov;16(11):1845; author reply 1845-6. Epub 2005 Jun 21. No abstract available.

PMID:
15972276
49.

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.

Pitini V, Teti D, Arrigo C, Righi M.

Br J Haematol. 2004 Dec;127(5):477. No abstract available.

PMID:
15566349
50.

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Pitini V, Arrigo C, Righi M.

Cancer. 2004 Dec 15;101(12):2900-1; author reply 2901-2. No abstract available.

Supplemental Content

Loading ...
Support Center